Thin primary cutaneous malignant melanoma: A prognostic tree for 10-year metastasis is more accurate than American joint committee on cancer staging

被引:157
作者
Gimotty, PA
Guerry, DP
Ming, ME
Elenitsas, R
Xu, XW
Czerniecki, B
Spitz, F
Schuchter, L
Elder, D
机构
[1] Univ Penn, Dept Biostat & Epidemiol, Sch Med, Philadelphia, PA 19104 USA
[2] Univ Penn, Dept Med, Sch Med, Philadelphia, PA 19104 USA
[3] Univ Penn, Dept Dermatol, Sch Med, Philadelphia, PA 19104 USA
[4] Univ Penn, Dept Pathol & Lab Med, Sch Med, Philadelphia, PA 19104 USA
[5] Univ Penn, Dept Surg, Sch Med, Philadelphia, PA 19104 USA
关键词
D O I
10.1200/JCO.2004.12.015
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose The majority of invasive primary melanomas are thin (less than or equal to 1.00 mm). Since the current staging system imperfectly predicts outcome in patients with such lesions, we sought to develop a more effective classification scheme to better identify both patients at high risk of metastasis who are candidates for further staging and therapy and those with little risk. Patients and Methods This prospective cohort study included 884 patients who had thin invasive melanomas. A tree-structured analysis of 10-year metastasis was used to develop a new classification scheme. Results The overall 10-year metastasis rate was 6.5% (95% CI, 4.8% to 8.1%). The prognostic tree defined four risk groups: high-risk: men with vertical growth phase (VGP) lesions that had mitotic rates (MRS) greater than 0, and for whom the 10-year metastasis rate was 31% (22% to 42%; n = 90); moderate-risk: women with VGP lesions that had MRs greater than 0 and for whom the rate was 13% (9% to 18%; n = 136); low-risk: patients with VGP lesions that had MR of 0 for whom the rate was 4% (2% to 7%; n = 247); and minimal-risk: patients with invasive lesions without VGP for whom the rate was 0.5% (0% to 1.2%; n = 411). Survival curves differed significantly among the four groups (P < .001). Conclusion Growth phase, mitotic rate, and sex are important prognostic factors for patients with thin melanomas, and they identify subgroups at substantial risk for metastasis. After validation in other populations, the proposed prognostic tree will be useful in the design of clinical trials and clinical management. (C) 2004 by American Society of Clinical Oncology.
引用
收藏
页码:3668 / 3676
页数:9
相关论文
共 46 条
[1]  
[Anonymous], 2002, AJCC CANC STAGING HD
[2]   A long-term analysis of 1018 patients with melanoma by classic Cox regression and tree-structured survival analysis at a major referral center: Implications on the future of cancer staging [J].
Averbook, BJ ;
Fu, PF ;
Rao, JS ;
Mansour, EG .
SURGERY, 2002, 132 (04) :589-602
[3]   Prognostic factors analysis of 17,600 melanoma patients: Validation of the American Joint Committee on Cancer melanoma staging system [J].
Balch, CM ;
Soong, SJ ;
Gershenwald, JE ;
Thompson, JF ;
Reintgen, DS ;
Cascinelli, N ;
Urist, M ;
McMasters, KM ;
Ross, MI ;
Kirkwood, JM ;
Atkins, MB ;
Thompson, JA ;
Coit, DG ;
Byrd, D ;
Desmond, R ;
Zhang, YT ;
Liu, PY ;
Lyman, GH ;
Morabito, A .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3622-3634
[4]   Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma [J].
Balch, CM ;
Buzaid, AC ;
Soong, SJ ;
Atkins, MB ;
Cascinelli, N ;
Coit, DG ;
Fleming, ID ;
Gershenwald, JE ;
Houghton, A ;
Kirkwood, JM ;
McMasters, KM ;
Mihm, MF ;
Morton, DL ;
Reintgen, DS ;
Ross, MI ;
Sober, A ;
Thompson, JA ;
Thompson, JF .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (16) :3635-3648
[5]  
Beahrs OH, 1988, MANUAL STAGING CANC, V3rd
[6]   Incidence of sentinel node metastasis in patients with thin primary melanoma (≤1 mm) with vertical growth phase [J].
Bedrosian, I ;
Faries, MB ;
Guerry, D ;
Elenitsas, R ;
Schuchter, L ;
Mick, R ;
Spitz, FR ;
Bucky, LP ;
Alavi, A ;
Elder, DE ;
Fraker, DL ;
Czerniecki, BJ .
ANNALS OF SURGICAL ONCOLOGY, 2000, 7 (04) :262-267
[7]  
Breiman L., 1998, CLASSIFICATION REGRE
[8]  
Busam KJ, 2001, AM J CLIN PATHOL, V115, P856
[9]   MODEL PREDICTING SURVIVAL IN STAGE-I MELANOMA BASED ON TUMOR PROGRESSION [J].
CLARK, WH ;
ELDER, DE ;
GUERRY, D ;
BRAITMAN, LE ;
TROCK, BJ ;
SCHULTZ, D ;
SYNNESTVEDT, M ;
HALPERN, AC .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1989, 81 (24) :1893-1904
[10]  
Clemente CG, 1996, CANCER, V77, P1303, DOI 10.1002/(SICI)1097-0142(19960401)77:7<1303::AID-CNCR12>3.0.CO